Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
The interest in recent application of NSAIDS effectiveness and
responsiveness in heart related conditions may be compared with the role
in interstitial fibrosis in heart failure or rapid atrial pacing models
of AF, directly compared with angiotensin-II mediated remodeling. Thus
the indirect pathways in MAP kinases and myocyte hypertrophy, fibroblast
proliferation, accumulation of collagen and apoptosis (Goette A et al. Signal transduction system and AF. Cardiovasc Res 2002 ; 54: 247-258) would
be valuable clues in this area.
Similar considerations derived from pros and cons derived from inhibitors
of COX2 (McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclo-oxigenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxigenase 2. JAMA 2006; 296:
1633-44) and the concept of addressing an important clinical question, the
comparison group receiving the best available active treatment in NSAIDS,
and controversies around secondary effects similar to COX2 inhibitors
would also be relevant questions.
Ref.
-Psaty B , Weiss N .NSAID trials and the choice of comparators - Questions of public health importance. NEJM 2007; 356: 328-330.
-Savelieva I , Camm J. Update on AF. Clin Cardiol 2008; 31: 55-62
Competing interests:
No competing interests
13 July 2011
Sabino Guillermo Echebarria Mendieta
MD neurologist.
H San Eloy ( Barakaldo-Bizkaia ) district clinics.Osakidetza-Basque Health Service
NSAIDS and atrial fibrillation
The interest in recent application of NSAIDS effectiveness and
responsiveness in heart related conditions may be compared with the role
in interstitial fibrosis in heart failure or rapid atrial pacing models
of AF, directly compared with angiotensin-II mediated remodeling. Thus
the indirect pathways in MAP kinases and myocyte hypertrophy, fibroblast
proliferation, accumulation of collagen and apoptosis (Goette A et al. Signal transduction system and AF. Cardiovasc Res 2002 ; 54: 247-258) would
be valuable clues in this area.
Similar considerations derived from pros and cons derived from inhibitors
of COX2 (McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclo-oxigenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxigenase 2. JAMA 2006; 296:
1633-44) and the concept of addressing an important clinical question, the
comparison group receiving the best available active treatment in NSAIDS,
and controversies around secondary effects similar to COX2 inhibitors
would also be relevant questions.
Ref.
-Psaty B , Weiss N .NSAID trials and the choice of comparators - Questions of public health importance. NEJM 2007; 356: 328-330.
-Savelieva I , Camm J. Update on AF. Clin Cardiol 2008; 31: 55-62
Competing interests: No competing interests